Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results

New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.

They correspond to U.K.'s short-acting psychedelic therapies developer Small Pharma's (OTC:DMTTF) open-label Phase 1b study assessing the joint work of its "native" DMT compound, SPL026 and selective serotonin reuptake inhibitors (SSRIs.) Read more HERE.

Canadian Practitioners Can Now Enroll In MDMA-Assisted Psychotherapy Training Program, Legal Medical Psilocybin Access For Veteran Approved

Canadian not-for...